Roberts Glore & Co. Inc. IL purchased a new position in Bio-Techne Corp (NASDAQ:TECH – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 21,541 shares of the biotechnology company’s stock, valued at approximately $1,522,000.
Other institutional investors have also recently made changes to their positions in the company. Jupiter Topco LLC bought a new position in shares of Bio-Techne in the second quarter worth approximately $4,818,000. Kintayl Capital LP bought a new stake in Bio-Techne during the 2nd quarter valued at $1,603,000. Hsbc Holdings PLC purchased a new stake in Bio-Techne during the 2nd quarter valued at $17,110,000. Canada Pension Plan Investment Board purchased a new stake in Bio-Techne during the 2nd quarter valued at $21,781,000. Finally, Legal & General Group Plc bought a new stake in Bio-Techne in the 2nd quarter worth $19,514,000. Hedge funds and other institutional investors own 98.95% of the company’s stock.
Bio-Techne Price Performance
Shares of NASDAQ TECH opened at $72.33 on Wednesday. Bio-Techne Corp has a 1 year low of $43.19 and a 1 year high of $72.62. The stock has a market capitalization of $11.34 billion, a P/E ratio of 62.90, a P/E/G ratio of 8.62 and a beta of 1.28. The company’s 50-day moving average is $69.93 and its 200 day moving average is $59.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.55 and a quick ratio of 3.35.
Bio-Techne Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Monday, August 24th will be given a dividend of $0.65 per share. This is a boost from Bio-Techne’s previous quarterly dividend of $0.08. This represents a $2.60 annualized dividend and a dividend yield of 3.6%. The ex-dividend date is Monday, August 24th. Bio-Techne’s dividend payout ratio is presently 27.83%.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on TECH shares. Piper Sandler initiated coverage on shares of Bio-Techne in a research note on Thursday, June 11th. They set a “neutral” rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft cut Bio-Techne from a “buy” rating to a “hold” rating and set a $73.00 target price on the stock. in a research note on Friday, June 26th. Robert W. Baird upped their price target on Bio-Techne from $49.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Wells Fargo & Company cut Bio-Techne from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. Finally, Zacks Research lowered Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Two research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $68.92.
Check Out Our Latest Research Report on TECH
Bio-Techne Company Profile
Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.
Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.
Read More
- Five stocks we like better than Bio-Techne
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
